Drug Profile
BMS 986224
Alternative Names: BMS-986224Latest Information Update: 20 Mar 2020
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic heart failure
Most Recent Events
- 10 Mar 2020 Discontinued - Phase-I for Chronic heart failure (In volunteers) in USA (PO) (NCT03281122)
- 10 Mar 2020 Discontinued - Phase-I for Chronic heart failure in United Kingdom, Spain, Poland, Czech Republic, Netherlands (PO) (NCT03281122)
- 10 Mar 2020 Discontinued - Phase-I for Chronic heart failure in USA (PO) (NCT03281122)